Literature DB >> 19996319

Modulation of the human glucuronosyltransferase UGT1A pathway by splice isoform polypeptides is mediated through protein-protein interactions.

Judith Bellemare1, Mélanie Rouleau1, Mario Harvey1, Chantal Guillemette2.   

Abstract

This study investigated the molecular mechanisms underlying the regulatory effect of the newly discovered 45-kDa enzymatically inactive UGT1A spliced polypeptides, named isoform i2, upon UGT1A-mediated glucuronidation. Initially, using an inducible system that mimics the relative abundance of isoforms 1 and 2 of UGT1A1 in human tissues, the rates of formation of glucuronides were significantly reduced. We then used a heterologous system constitutively expressing both isoforms i1 and i2 for an in-depth investigation of the presence of spliced i2 on glucuronidation kinetics. UGT1A1, UGT1A7, and UGT1A8 were selected as candidates for these studies. In all cases, co-expression of i1 and i2 in HEK293 cells leads to a significant reduction of the velocity of the glucuronidation reaction without affecting the affinity (K(m) (app)) for all substrates tested and the K(m) for the co-substrate, UDP-glucuronic acid. The data are consistent with a dominant-negative model of inhibition but do not sustain with an UGT1A_i2-mediated inhibition by competitive binding for substrate or the co-substrate. In contrast, the data from the co-immunoprecipitation experiments are indicative of the existence of a mixture homo-oligomeric (i1-i1 or i2-i2) and hetero-oligomeric (i1-i2) complexes in which the i2-i2 and i1-i2 subunits would be inactive. Thus, protein-protein interactions are likely responsible for the inhibition of active UGT1A_i1 by i2 spliced polypeptides. This new regulatory mechanism may alternatively modulate cellular response to endo/xeno stimulus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19996319      PMCID: PMC2823500          DOI: 10.1074/jbc.M109.083139

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Oligomerization of the UDP-glucuronosyltransferase 1A proteins: homo- and heterodimerization analysis by fluorescence resonance energy transfer and co-immunoprecipitation.

Authors:  Theresa N Operaña; Robert H Tukey
Journal:  J Biol Chem       Date:  2006-12-19       Impact factor: 5.157

2.  Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus.

Authors:  Q H Gong; J W Cho; T Huang; C Potter; N Gholami; N K Basu; S Kubota; S Carvalho; M W Pennington; I S Owens; N C Popescu
Journal:  Pharmacogenetics       Date:  2001-06

Review 3.  The UDP-glucuronosyltransferases as oligomeric enzymes.

Authors:  Moshe Finel; Mika Kurkela
Journal:  Curr Drug Metab       Date:  2008-01       Impact factor: 3.731

4.  UDP-glucuronosyltransferase, the role of the amino terminus in dimerization.

Authors:  R Meech; P I Mackenzie
Journal:  J Biol Chem       Date:  1997-10-24       Impact factor: 5.157

5.  An internal signal sequence mediates the targeting and retention of the human UDP-glucuronosyltransferase 1A6 to the endoplasmic reticulum.

Authors:  M Ouzzine; J Magdalou; B Burchell; S Fournel-Gigleux
Journal:  J Biol Chem       Date:  1999-10-29       Impact factor: 5.157

6.  Alternative-splicing forms of the major phase II conjugating UGT1A gene negatively regulate glucuronidation in human carcinoma cell lines.

Authors:  J Bellemare; M Rouleau; M Harvey; B Têtu; C Guillemette
Journal:  Pharmacogenomics J       Date:  2009-12-08       Impact factor: 3.550

Review 7.  Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.

Authors:  K Venkatakrishnan; L L Von Moltke; D J Greenblatt
Journal:  J Clin Pharmacol       Date:  2001-11       Impact factor: 3.126

8.  A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini.

Authors:  J K Ritter; F Chen; Y Y Sheen; H M Tran; S Kimura; M T Yeatman; I S Owens
Journal:  J Biol Chem       Date:  1992-02-15       Impact factor: 5.157

9.  Genetic diversity at the UGT1 locus is amplified by a novel 3' alternative splicing mechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activity.

Authors:  Hugo Girard; Eric Lévesque; Judith Bellemare; Kim Journault; Bertrand Caillier; Chantal Guillemette
Journal:  Pharmacogenet Genomics       Date:  2007-12       Impact factor: 2.089

10.  Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities.

Authors:  Ryoichi Fujiwara; Miki Nakajima; Hiroyuki Yamanaka; Miki Katoh; Tsuyoshi Yokoi
Journal:  Drug Metab Dispos       Date:  2007-07-09       Impact factor: 3.922

View more
  14 in total

1.  Quantification of Hepatic UDP glucuronosyltransferase 1A splice variant expression and correlation of UDP glucuronosyltransferase 1A1 variant expression with glucuronidation activity.

Authors:  Nathan R Jones; Dongxiao Sun; Willard M Freeman; Philip Lazarus
Journal:  J Pharmacol Exp Ther       Date:  2012-06-01       Impact factor: 4.030

2.  Quantitative profiling of the UGT transcriptome in human drug-metabolizing tissues.

Authors:  A Tourancheau; M Rouleau; S Guauque-Olarte; L Villeneuve; I Gilbert; A Droit; C Guillemette
Journal:  Pharmacogenomics J       Date:  2017-04-25       Impact factor: 3.550

Review 3.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

4.  Post-transcriptional Regulation of UGT2B10 Hepatic Expression and Activity by Alternative Splicing.

Authors:  Adrien Labriet; Eric P Allain; Michèle Rouleau; Yannick Audet-Delage; Lyne Villeneuve; Chantal Guillemette
Journal:  Drug Metab Dispos       Date:  2018-02-09       Impact factor: 3.922

5.  Characterization of dibenzo[a,l]pyrene-trans-11,12-diol (dibenzo[def,p]chrysene) glucuronidation by UDP-glucuronosyltransferases.

Authors:  Kristine C Olson; Dongxiao Sun; Gang Chen; Arun K Sharma; Shantu Amin; Ira J Ropson; Thomas E Spratt; Philip Lazarus
Journal:  Chem Res Toxicol       Date:  2011-08-05       Impact factor: 3.739

6.  Identification and functional characterization of a novel UDP-glucuronosyltransferase 2A1 splice variant: potential importance in tobacco-related cancer susceptibility.

Authors:  Ryan T Bushey; Philip Lazarus
Journal:  J Pharmacol Exp Ther       Date:  2012-09-13       Impact factor: 4.030

7.  The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure.

Authors:  Michael H Court; Marina Freytsis; Xueding Wang; Inga Peter; Chantal Guillemette; Suwagmani Hazarika; Su X Duan; David J Greenblatt; William M Lee
Journal:  J Pharmacol Exp Ther       Date:  2013-02-13       Impact factor: 4.030

8.  The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene–environment interactions.

Authors:  Andrea Y Angstadt; Terryl J Hartman; Samuel M Lesko; Joshua E Muscat; Junjia Zhu; Carla J Gallagher; Philip Lazarus
Journal:  Genes Chromosomes Cancer       Date:  2014-06       Impact factor: 5.006

9.  UDP-Glucuronosyltransferase (UGT)-mediated attenuations of cytochrome P450 3A4 activity: UGT isoform-dependent mechanism of suppression.

Authors:  Yuu Miyauchi; Yoshitaka Tanaka; Kiyoshi Nagata; Yasushi Yamazoe; Peter I Mackenzie; Hideyuki Yamada; Yuji Ishii
Journal:  Br J Pharmacol       Date:  2020-01-23       Impact factor: 8.739

Review 10.  Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms?

Authors:  Aleksandra M Dudek; Anne J Grotenhuis; Sita H Vermeulen; Lambertus A L M Kiemeney; Gerald W Verhaegh
Journal:  Int J Mol Sci       Date:  2013-06-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.